合成受容体内の非共性相互作用は,ゲスト結合を強化することができます
Zaida Rodriguez-Docampo1, Sofia I Pascu, Stefan Kubik
1Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom.
Journal of the American Chemical Society
|August 24, 2006
まとめ
ビスコペプチドアニオン受容体は,硫酸塩とヨウ素をマイクロモラー親和性で結合する. 感受体内の水害性相互作用は,水溶液における結合安定性を著しく高めます.
科学分野:
- 超分子化学 超分子化学
- ホスト・ゲスト・ケミストリー
- 化学生物学 化学生物学とは
背景:
- アニオン認識は,生物学的プロセスや化学センサーにおいて極めて重要です.
- 周期性ペプチドは,アニオン受容体を設計するための多用途の支架です.
- 結合メカニズムを理解することは,高親和性受容体の開発の鍵です.
研究 の 目的:
- ビサイクロペプチドアニオン受容体の結合特性を調査する.
- アニオン複合体の安定性における受容体内相互作用の役割を明らかにする.
- ホスト・ゲストの親密さを高めるための戦略を探求する.
主な方法:
- アニオン複合体の構造的決定のためのX線結晶学.
- 熱力学的結合パラメータと溶媒効果を分析するためのマイクロカロリメトリー.
- モノメアサイクロペプチドを様々な溶媒で比較した研究.
主要な成果:
- ビサイクロペプチド受容体は水中の硫酸塩とヨウ素をマイクロモラー親和性で結合する.
- 結晶構造はペプチド環の間に結合したアニオンを明らかにし,それは水害性相互作用によって安定化される.
- マイクロカロリメトリーは,水害性相互作用が溶解コストを補償することを示しています.
結論:
- 内受容体内非共性相互作用は,アニオン複合体の安定性に大きく貢献する.
- 内部相互作用を通じて分子認識を強化することは,宿主-ゲスト化学の有望な戦略です.
- この研究は,強化された親和性を持つ高度なアニオン受容体の設計に関する洞察を提供します.
さらに関連する動画
関連する概念動画
Noncovalent Attractions in Biomolecules
65.3K
Noncovalent attractions are associations within and between molecules that influence the shape and structural stability of complexes. These interactions differ from covalent bonding in that they do not involve sharing of electrons.
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
65.3K
Noncovalent Attractions in Biomolecules
19.6K
No description available
19.6K
Drug-Receptor Interactions
7.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
Drug-Receptor Interaction: Antagonist
5.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
The Equilibrium Binding Constant and Binding Strength
15.3K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.3K


